What the FDA labels say about taking them together
Ezetimibe and fenofibrate
Ezetimibe's FDA label of November 25, 2025 names fenofibrate in its contraindications section; the fenofibrate labels PlainMeds reads (3) do not name ezetimibe. The ezetimibe label: “Both fenofibrate and ezetimibe may increase cholesterol excretion into the bile, leading to cholelithiasis. Co-administration of ZETIA with fibrates other than fenofibrate is not recommended.”
Check it at the source: the ezetimibe FDA label on DailyMed (effective November 25, 2025, Organon LLC); the fenofibrate FDA label on DailyMed (effective April 29, 2024, A-S Medication Solutions).
What does the ezetimibe label say about fenofibrate?
Ezetimibe label, contraindicationsWhen used in combination with a statin, fenofibrate, or other LDL-C lowering therapy, ZETIA is contraindicated in patients for whom a statin, fenofibrate, or other LDL-C lowering therapy are contraindicated.
Ezetimibe label, drug interactionsClinical Impact: Both fenofibrate and ezetimibe may increase cholesterol excretion into the bile, leading to cholelithiasis. Co-administration of ZETIA with fibrates other than fenofibrate is not recommended. Intervention: If cholelithiasis is suspected in a patient receiving ZETIA and fenofibrate, gallbladder studies are indicated, and alternative lipid-lowering therapy should be considered.
Ezetimibe label, warnings and precautionsWARNINGS AND PRECAUTIONS Risks Associated with Combination Treatment with a Statin, Fenofibrate, or Other LDL-C Lowering Therapies:
Source: FDA drug label (Zetia), Organon LLC, effective November 25, 2025 (SPL set 174e45e0-45bb-48b7-9e60-8f6cfc1d22bb), via openFDA; the full label on DailyMed
What does the fenofibrate label say about ezetimibe?
Fenofibrate's label (effective April 29, 2024) and its 2 other brand-application labels do not name ezetimibe in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Tricor), NDA021656 (Abbvie), as published by A-S Medication Solutions, effective April 29, 2024 (SPL set 84b2af1b-365e-4723-ac5f-bc826ec47772), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Ezetimibe | Fenofibrate | |
|---|---|---|
| Labeled for | High cholesterol | High cholesterol, High triglycerides |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.0667 per tablet 10 mg tablet | $0.103 per tablet 160 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once